Titan Medical
Employees
Market cap
€4.2m
Enterprise valuation
€2m (Public information from Sep 2024)
Share price
CAD0.05 TMD.TO
Toronto Ontario (HQ)
Financials
Estimates*
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | 20.0m | 20.1m | - | 17.6m |
| EBITDA | (17.9m) | (37.7m) | (61.2m) | 2.6m | (29.6m) | (43.8m) | 10.8m |
| % EBITDA margin | - | - | - | 13 % | (147 %) | - | 61 % |
| Profit | (31.9m) | (21.5m) | (41.9m) | (24.2m) | (14.9m) | (42.5m) | 7.0m |
| % profit margin | - | - | - | (121 %) | (74 %) | - | 39 % |
| EV / revenue | - | - | - | 5.9x | 2.0x | - | 0.0x |
| EV / EBITDA | -4.9x | -0.4x | -0.3x | 44.3x | -1.4x | -1.7x | 0.1x |
| R&D budget | 12.3m | 31.2m | 51.4m | 7.9m | 38.0m | 33.0m | <1m |
| R&D % of revenue | - | - | - | 40 % | 189 % | - | 2 % |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| N/A | $8.3m | Post IPO Equity | |
| N/A | $9.2m | Post IPO Equity | |
| N/A | $7.6m | Post IPO Equity | |
| N/A | $6.6m | Post IPO Equity | |
| N/A | $34.8m | Post IPO Equity | |
| N/A | $12.1m | Post IPO Equity | |
| N/A | $7.9m | Post IPO Equity | |
| N/A | $7.0m | Post IPO Equity | |
| N/A | CAD23.0m | Post IPO Equity | |
| N/A | $19.2m | Post IPO Equity | |
| N/A | $25.0m | Post IPO Equity | |
$35.0m | Post IPO Equity | ||
| N/A | $1.5m | Post IPO Debt | |
| N/A | $23.0m | Post IPO Equity | |
| N/A | $10.6m | Post IPO Debt | |
| Total Funding | - | ||
